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Objective/background: There is a paucity of published data on the effect of tuberculosis (TB)
chemotherapy on nitric oxide (NO) synthesis and metabolism in newly diagnosed and
relapsed patients with or without multidrug-resistant TB (MDR-TB).
Methods: The pattern of NO response in 140 patients with pulmonary TB, including 74 with
MDR-TB (1st group) and 66 without MDR-TB (2nd group) has been studied and compared
with the NO status of 30 healthy donors (3rd group). Patients comprised those with newly
diagnosed pulmonary TB (Subgroups 1B and 2B) and recurrent or relapsed TB (Subgroups
1A and 2A). The NO status was assessed by measuring inducible NO synthase (iNOS),
nitrites, and nitrates levels. This was measured prior to treatment initiation and 2 months
after the prescribed chemotherapy.
Results: Increased levels of NO indices were found in patients with TB when compared with
healthy controls—1st group: iNOS, 231.6 ± 6.65 pmol/min/mgB; nitrites, 5.626 ± 0.15 lmol/L;
and nitrates, 62.89 ± 1.42 lmol/L (Subgroup 1A: iNOS, 208.40 ± 8.26 pmol/min/mgB; nitrites,
5.027 ± 0.17 lmol/L; and nitrates, 59.29 ± 1.79 lmol/L and Subgroup 1B: iNOS, 260.4
± 8.56 pmol/min/mgB; nitrites, 6.371 ± 0.19 lmol/L; and nitrates, 67.36 ± 2.03 lmol/L); 2nd
group: iNOS, 286.3 ± 5.92 pmol/min/mgB; nitrites, 6.747 ± 0.17 lmol/L; and nitrates, 72.02
± 1.43 lmol/L (Subgroup 2A: iNOS, 260.9 ± 14.12 pmol/min/mgB; nitrites, 5.686 ± 0.20 lmol/
L; and nitrates, 66.26 ± 1.89 lmol/L and Subgroup 2B: iNOS, 293.7 ± 6.13 pmol/min/mgB;
nitrites, 7.059 ± 0.19 lmol/L; and nitrates, 73.72 ± 1.71 lmol/L) versus healthy controls
(iNOS, 81.03 ± 2.36 pmol/min/mgB; nitrites, 3.83 ± 0.093 lmol/L; and nitrates, 37.98
± 1.30 lmol/L). After 2 months of chemotherapy, a significant decrease in NO indicators
was observed in the patients with TB, particularly in those without MDR-TB—1st group:
iNOS, 114.9 ± 3.2 pmol/min/mgB; nitrites, 4.21 ± 0.13 lmol/L; and nitrates, 46.65
± 1.04 lmol/L (Subgroup 1A: iNOS, 125.3 ± 4.5 pmol/min/mgB; nitrites, 4.42 ± 0.14 lmol/L;
and nitrates, 49.38 ± 1.30 lmol/L and Subgroup 1B: iNOS, 102 ± 3.53 pmol/min/mgB; nitrites,
3.93 ± 0.13 lmol/L; and nitrates, 43.26 ± 1.50 lmol/L) and 2nd group: iNOS, 91.4 ± 2.53 pmol/
min/mgB; nitrites, 3.67 ± 0.09 lmol/L; and nitrates, 35.65 ± 1.06 lmol/L (Subgroup 2A: iNOS,kt Nauky,
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resistant tuberculosis undergoing the intensive phase106.7 ± 5.2 pmol/min/mgB; nitrites, 4.04 ± 0.19 lmol/L; and nitrates-40.53 ± 1.83 lmol/L and
Subgroup 2B, iNOS, 86.7 ± 2.59 pmol/min/mgB; nitrites, 3.56 ± 0.1 lmol/L; and nitrates,
34.22 ± 1.19 lmol/L). The decline in NO activity was less prominent in patients with recur-
rent TB and MDR-TB, which suggests lower level of immunologic and reparative processes
in such patients.
Conclusion: In patients with pulmonary TB, significantly higher levels of NO activity were
observed as compared with the levels in healthy individuals. In patients with recurrent
TB and MDR-TB, significantly lower levels of NO indicators were observed in comparison
with patients with newly diagnosed pulmonary TB. After 2 months on chemotherapy, a sig-
nificant decrease in iNOS activity and NO metabolites was observed in patients with pul-
monary TB, but the decrease in NO indicators was manifested mostly in the newly
diagnosed pulmonary TB patients and patients without MDR-TB as opposed to patients
with recurrent TB and MDR-TB, which suggests lower levels of immunologic and reparative
processes in such patients. Therefore, the levels of nitrites and nitrates as well as iNOS
activity may serve as additional diagnostic criteria to differentiate MDR-TB from nonresis-
tant TB in patients with relapsed and newly diagnosed TB. Easily assessed NO-related
markers can also serve as predictors of treatment outcome because patients with drug-
susceptible strains had lower NO output approaching levels found in controls.Conflicts of interest
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